News in Brief
Maria Gomez Sanchez Presents at International Symposium of Physiotherapy & Equine Rehabilitation in Madrid
Maria Gomez Sanchez from the UCD Veterinary Hospital's Animal Rehabilitation Clinic recently presented at the Spanish Association of Animal Physiotherapy / Asociación Española de fisioterapia aplicada en animales (AEFA) International Symposium of Physiotherapy & Equine Rehabilitation in Madrid.
Maria was invited by AEFA to speak at this multidisciplinary event and her presentation on 'Fascia, Tesengrity and its clinical applications' was received with great enthusiasm. The event was very much focused on a ‘One Health’ collaborative approach to equine physiotherapy and rehabilitation, and attendees came from a range of backgrounds - vets, physios, riders, farriers and a number of equine organisations were represented.
Angel Shark Project: Ireland Launched
The recently launched Angel Shark Project: Ireland, led by the Irish Elasmobranch Group (IEG) aims to focus on one of Ireland's most threatened species, the Angelshark. Those involved in the project will work closely with fishers and communities to gather both current and historical Angelshark records, vital to help safeguard this species in Ireland. In 2022, the IEG, in partnership with (opens in a new window)Project SIARC and (opens in a new window)Inland Fisheries Ireland hosted a CSI Of The Sea Angelshark examination at the UCD Veterinary Hospital. Find out more about this initiative on our News & Events page.
UCD Researchers Behind Novel Mucolytic Drug Receive 2023 NovaUCD Innovation Award
Professor Stefan Oscarson, Professor in Chemical Biology at the UCD School of Chemistry and Professor Stephen Carrington, retired Professor of Veterinary Anatomy at the UCD School of Veterinary Medicine, have been named recipients of the 2023 NovaUCD Innovation Award. The award is in recognition of their successful and longstanding research collaboration with Professor John Fahy, University of California, San Francisco (UCSF) to understand why mucus in the lungs of people with respiratory diseases is thick, sticky and difficult to cough up and to develop new treatment strategies to help such patients breathe more easily. The UCD-UCSF research collaboration led to the filing of a patent application for a novel mucolytic drug to address a large unmedical need for patients with mucus-associated lung diseases. These diseases include, chronic obstructive pulmonary diseases (COPD), asthma, cystic fibrosis and bronchiectasis. Find out more about the UCD-UCSF research collaboration on our News & Events page.